Geron Corporation (NASDAQ:GERN)  got bad news about its key imetelstat drug, as the FDA issued a clinical hold on the treatment for multiple myeloma and essential thrombocythemia. Geron Corporation (NASDAQ:GERN) stock performance was -61.59% in last session and finished the day at $1.69. Traded volume was 46,444,384 million shares in the last session and the average volume of the stock remained 4.64 million shares. The beta of the stock remained 1.67. Geron Corporation (NASDAQ:GERN) insider ownership is 0.10%.

Pfizer Inc. (NYSE:PFE) said Wednesday that its blockbuster vaccine against pneumonia, blood and other infections met its goal of preventing illness in vulnerable elderly patients in a huge study required by U.S. regulators. Pfizer Inc. (NYSE:PFE) dropped -1.36 percent to $31.98 yesterday on volume of 32.52 million shares. The intra-day range of the stock was $31.93 to $32.57. Pfizer Inc. (NYSE:PFE) has a market capitalization of $204.64 million.

Oxigene Inc (NASDAQ:OXGN)  said its experimental drug Zybrestat, combined with Roche’s (ROG.VX) cancer drug Avastin, significantly slowed progression of recurrent ovarian cancer better than Avastin alone in a mid-stage clinical trial. OXiGENE Inc (NASDAQ:OXGN)’s stock on Mar 12, 2014 reported an increase of 77.27% to the closing price of $4.29. Its fifty two weeks range is $1.96 -$5.40. The total market capitalization recorded $49.20 million. The overall volume in the last trading session was 29,290,814 million shares. In its share capital, OXiGENE Inc (NASDAQ:OXGN) has 2.64 million outstanding shares.

Gilead Sciences (NASDAQ:GILD) EVP Paul Rutherford Carter sold 16,728 shares of Gilead Sciences stock in a transaction dated Monday, March 10th. On Wednesday, shares of Gilead Sciences, Inc. (NASDAQ:GILD) dropped -0.15% to close the day at $79.72. Company return on investment (ROI) is 18.70% and its monthly performance is recorded as -1.56%. Gilead Sciences, Inc. (NASDAQ:GILD) quarterly revenue growth is 6.02%.